To evaluate the predictive value of the peri-bowel fat attenuation index (FAI) for disease progression in inflammatory bowel disease (IBD) patients, highlighting its potential clinical significance.
Key Findings:
The peri-bowel FAI can effectively detect peri-bowel fat inflammation, with a sensitivity of X% and specificity of Y%.
FAI may serve as an independent predictor of disease progression in IBD patients, outperforming current noninvasive risk factors.
Current noninvasive risk factors do not fully capture the predictive capability of FAI, indicating a need for integration into clinical practice.
Interpretation:
The peri-bowel FAI provides a novel, noninvasive method to assess inflammation in IBD, potentially guiding treatment strategies and improving patient outcomes, thus enhancing the 'treat-to-target' approach.
Limitations:
Retrospective design may introduce bias, particularly in data collection.
Limited generalizability due to specific inclusion criteria, suggesting the need for multicenter studies.
Dependence on the quality of CT imaging and interpretation, which may vary across institutions.
Conclusion:
The peri-bowel FAI is a promising biomarker for predicting disease progression in IBD, warranting further investigation to validate its clinical utility and explore its integration into routine practice.
